Ozanezumab  (Synonyms: GSK1223249)

Ozanezumab (GSK1223249) is a humanized, Fc-inactivated monoclonal antibody that targets the nervous system protein Nogo-A. Ozanezumab promotes neurite outgrowth and axonal regeneration by neutralizing Nogo-A signaling. Ozanezumab is used for research on neurodegenerative diseases such as amyotrophic lateral sclerosis and multiple sclerosis^[1][2][3].

Human IgG1 kappa

Human IgG1 kappa, Isotype Control

Human

RTN4/NOGO

Ozanezumab reduces or reverses the inhibitory effect on axonal growth in a dose-dependent manner in cultured cerebellar granule neurons from postnatal rats^[2].
Ozanezumab (0.7-100 μg/mL (4.67 to 667 nM); 1 h pre-incubation, 24 h total) dose-dependently neutralizes the inhibitory effect of GST-Nogo-A on axonal growth of cultured postnatal rat cerebellar granule neurons^[3].
Ozanezumab exhibits specific immunohistochemical staining in conserved neural tissues, muscle tissues, and some other tissues in Rattus norvegicus (rat), Macaca (monkey), and Oryctolagus cuniculus (rabbit, central nervous system), while additional species-specific staining is present in neuronal tissues, pituitary tissues, and cardiac tissues of rodents and primates^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

57142  [NCBI]

Q9NQC3

ELISA, FACS, Functional assay

Unconjugated

The product can be reconstituted/diluted with sterile PBS or saline.

145.227 kDa

1310680-64-8

Liquid

Colorless to light yellow

[Ozanezumab]

Shipping with dry ice.

Please refer to the lot-specific COA for specific buffer information.

Please store the product under the recommended conditions in the Certificate of Analysis.

• 
  Human IgG1 kappa

• 
  Flow Cytometry analysis of Hela cells labelling RTN4/NOGO (red) with Ozanezumab (anti-RTN4/NOGO) (HY-P99213). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG Isotype Control (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).

• [1]. Gharagozloo M, et al. Breaking the barriers to remyelination in multiple sclerosis. Curr Opin Pharmacol. 2022;63:102194.  [Content Brief]

  [2]. Meininger V, et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017;16(3):208-216.  [Content Brief]

  [3]. Anthony M. Lynch, et al. Non-clinical development of ozanezumab: a humanised antibody targeting the amino terminus of neurite outgrowth inhibitor A (Nogo-A), Toxicology Research, Volume 4, Issue 5, September 2015, Pages 1333–1343.